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CONSPECTUS
G
lycosylation is an essential form of post-translational modiﬁcation that regulates intracellular and extracellular
processes. Regrettably, conventional biochemical and genetic methods often fall short for the study of glycans,
because their structures are often not precisely deﬁned at the genetic level. To address this deﬁciency, chemists have
developed technologies to perturb glycan biosynthesis, proﬁle their presentation at the systems level, and perceive
their spatial distribution. These tools have identiﬁed potential disease biomarkers and ways to monitor dynamic changes
to the glycome in living organisms. Still, glycosylation remains the underexplored frontier of many biological sys-
tems. In this Account, we focus on research in our laboratory that seeks to transform the study of glycan function from
a challenge to routine practice.
In studies of proteins and nucleic acids, functional studies have often relied on genetic manipulations to perturb struc-
ture. Though not directly subject to mutation, we can determine glycan structure-function relationships by synthesizing
deﬁned glycoconjugates or by altering natural glycosylation pathways. Chemical syntheses of uniform glycoproteins and poly-
meric glycoprotein mimics have facilitated the study of individual glycoconjugates in the absence of glycan microheteroge-
neity. Alternatively, selective inhibition or activation of glycosyltransferases or glycosidases can deﬁne the biological roles
of the corresponding glycans. Investigators have developed tools including small molecule inhibitors, decoy substrates, and
engineered proteins to modify cellular glycans. Current approaches offer a precision approaching that of genetic control.
Genomic and proteomic proﬁling form a basis for biological discovery. Glycans also present a rich matrix of informa-
tion that adapts rapidly to changing environs. Glycomic and glycoproteomic analyses via microarrays and mass spectrom-
etry are beginning to characterize alterations in glycans that correlate with disease. These approaches have already identiﬁed
several cancer biomarkers. Metabolic labeling can identify recently synthesized glycans and thus directly track glycan dynam-
ics. This approach can highlight changes in physiology or environment and may be more informative than steady-state anal-
yses. Together, glycomic and metabolic labeling techniques provide a comprehensive description of glycosylation as a
foundation for hypothesis generation.
Direct visualization of proteins via the green ﬂuorescent protein (GFP) and its congeners has revolutionized the ﬁeld of
protein dynamics. Similarly, the ability to perceive the spatial organization of glycans could transform our understanding
of their role in development, infection, and disease progression. Fluorescent tagging in cultured cells and developing organ-
isms has revealed important insights into the dynamics of these structures during growth and development. These results
have highlighted the need for additional imaging probes.
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Virtually every class of biomolecule can be found in a glyco-
sylated form. This phenomenon extends from the glycopro-
teins, which we now know comprise ∼50% of the total
cellular proteome and >90% of the secreted proteome,
1,2 to
lipids, tRNA,
3 and many secondary metabolites (Figure 1). But
the question, “what do the glycans do?” remains unanswered
in many cases. Decades of research in the rapidly expanding
ﬁeld of glycobiology have provided some insights. For exam-
ple, glycans have been shown to govern biological homeo-
stasis, playing central roles in protein folding, trafﬁcking, and
stability,
4 and in organ development.
5 Inside cells, protein gly-
cosylation is thought to play a role in signaling, perhaps in
concert with phosphorylation.
6 Cell-surface glycans are poised
to mediate intercellular communication,
7 including pathogen
recognition,
8,9 and to distinguish self from non-self immuno-
logically.
10 In addition, the glycosylation state of both cell-
surface proteins and lipids responds to external stimuli and
internal cellular dysfunction. Thus, the dynamics of these mol-
ecules reﬂect the cell’s physiological state and can report on
disease.
11
Historically, approaches to studying glycans reﬂected the
standard tactics of biological inquiry that were developed in
the context of proteins and nucleic acids: (1) alter the struc-
ture or expression level and evaluate the biological conse-
quence (i.e., perturb); (2) deﬁne the molecular inventory as a
function of physiology (i.e., proﬁle); (3) visualize the molecule
in a living system to understand its distribution and dynam-
ics (i.e., perceive). Based primarily in genetics and biochemis-
try, the experimental tools used to accomplish these goals for
proteins and nucleic acids did not always translate to the
study of glycans. For example, perturbation of glycan struc-
tures can be achieved by genetic mutation of glycosyltrans-
ferases, but the effects of such mutations are often masked by
embryonic lethality or compensatory upregulation of redun-
dant enzymes.
12,13 Lectins and antibodies with deﬁned gly-
can speciﬁcities can be used to proﬁle cell-surface glycans and
to correlate global changes in their expression with develop-
mental stages and disease.
14 Until recently, however, the
available lectins and antibodies were limited in number.
Finally, visualizing glycans in living systems is an unmet chal-
lenge for which no conventional experimental approach is
suited. The ability to perceive these biopolymers as they
undergo dynamic changes within organisms could transform
our view of glycobiology.
New techniques derived from physical, analytical, and syn-
thetic chemistry are starting to address many of the inade-
quacies of the conventional toolbox as applied to glycans.
Several groups have contributed in important ways to the bur-
geoning ﬁeld of chemical glycobiology. Their contributions
include small molecules that interfere with glycan
biosynthesis,
15-17 glycopolymers that modulate carbohydrate
receptor activity,
18 and synthetic methods for assembling
glycoconjugates.
19-22 Furthermore, analytical tools such as
lectin microarrays and mass spectrometry are providing, for
the ﬁrst time, detailed pictures of the “glycome”.
23,24 Due to
restrictions of space, this Account will focus primarily on our
own efforts to develop small molecules to perturb, proﬁle, and
perceive glycans.
FIGURE 1. Examples of glycoconjugates. Many proteins are
glycosylated at asparagine (N-linked) or serine/threonine residues
(mucin-type O-linked and O-GlcNAc are shown). Lipids, secondary
metabolites, and tRNA are examples of other biomolecules found in
glycosylated form.
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Living Systems
Chemical Synthesis of Glycoconjugates. In principle, the
synthesis of chemically deﬁned glycoconjugates allows
researchers to perturb biological systems in a tightly controlled
fashion. Though syntheses of singly substituted glycopeptides
are routinely achieved, the complexity of most glycoproteins
and glycopeptides presents a formidable challenge. Full details
of this approach have been recently reviewed.
25 A notable
success comes from Danishefsky and colleagues who synthe-
sized portions of the highly glycosylated protein erythropoi-
etin A (EPO) by joining chemically synthesized glycopeptides
via native chemical ligation.
26 These glycosylated peptides
were more than 20 amino acids in length and contained elon-
gated N- and O-linked glycans, thus providing a framework for
the total synthesis of a complex glycoprotein. Semisynthesis
of a full-length glycoprotein, GlyCAM-1, has been achieved via
the combination of glycopeptide synthesis and expressed pro-
tein ligation technology. The protein included up to 13 sites
of O-linked glycosylation (R-GalNAc-modiﬁed serines and thre-
onines) located on two separate mucin domains of the pro-
tein.
27 Despite these remarkable achievements, the technical
challenges associated with glycoprotein syntheses will likely
prevent their routine application.
An alternative strategy to glycoprotein total synthesis is
the development of synthetically tractable glycoconjugate
analogs. Mucins are proteins containing repeating units of
densely glycosylated domains whose biological functions
often correspond to the degree of glycosylation. Recently
we have reported the use of chemically deﬁned mucin
mimics to study glycans in synthetic lipid bilayers and cell
surfaces.
28,29 The condensation of aminooxy-sugars with
polymethylvinylketone gave highly modiﬁed glycopolymers
(Figure 2). These glycoconjugates resembled native mucins
in size, macromolecular structure, and biophysical proper-
ties. Incorporated into synthetic membranes or cell surfaces,
these glycopolymers interact with carbohydrate binding pro-
teins (lectins) in a manner speciﬁc to the appended glycan’s
composition, arrangement, and stereochemistry. The poly-
mers also demonstrate surface two-dimensional mobilities
similar to cell-surface lipid-bound mucins. These polymers
are a promising alternative strategy for studying the role of
glycans in both intra- and intercellular receptor-mediated
signaling.
FIGURE 2. Structures of mucin-type O-linked glycosylation and the structure and synthesis of a mucin mimetic. (A) Mucin-type O-linked
glycosylation is characterized by densely functionalized arrays of glycans on a polypeptide backbone. (B) A derivatized polyvinylketone
backbone can approximate endogenous mucins. (C) The synthesis of mucin mimics proceeds by condensing aminooxy-GalNAc with
polyvinyl ketone. Extended sugars can also be incorporated.
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tors of glycan biosynthesis can alter glycan structures.
30 Cell-
surface glycans are constructed by the stochastic action of
spatially constrained ER- and Golgi-associated glycosyltrans-
ferases as their target glycoconjugates traverse the secretory
pathway. The roughly 250 glycosyltransferases predicted in
mammalian genomes are attractive targets for small mole-
cule inhibition and could help elucidate their roles in dynamic
cellular processes that are opaque to course-grained genetic
manipulations. To serve as useful tools for biological inquiry,
glycosyltransferase inhibitors must be selective for their tar-
get, active in cells, and potentially active in living organisms.
Several natural products are known inhibitors of glycosyla-
tion, including tunicamycin, which blocks the biosynthesis of
N-linked glycan precursors, and deoxynojirimycin, which
broadly inhibits certain glycan processing enzymes. These
molecules and their relatives have been widely employed to
study the effects of glycosylation on protein function, but off-
target effects limit their utility.
Chemical biologists have sought to expand upon this lim-
ited toolkit with the design of inhibitors that target speciﬁc
enzymes. Pioneering work by Imperiali and co-workers tar-
geted the enzymes responsible for the initiation of N-linked
glycosylation. The researchers synthesized a potent inhibitor
of oligosaccharyl transferase (OST), the enzyme that trans-
fers N-linked glycans to proteins in the ER.
31,32 The compound
was based on a constrained peptide that approximated the
natural substrate’s ASX turn. Once optimized for cell-based
environments, the compound promises to disrupt N-linked gly-
cosylation in a more reﬁned fashion than tunicamycin. Despite
this and other notable successes in this area, the structural
homology and functional overlap of the more than 200 gly-
cosyltransferases makes inhibition of individual glycosyltrans-
ferases a challenge.
Primers of Glycosylation. An alternative strategy for
modulating cellular glycan structures involves “primers of gly-
cosylation”. In general, these compounds are simple naturally
occurring sugars adorned with hydrophobic aglycones such as
benzyl, phenyl, and naphthyl groups. Including -xylosides,
33
R-benzyl GalNAc,
34 and various substituted disaccharides, the
primers act as competitive substrates for glycosyltransferases
inside cells.
35 At high concentrations, the primers out com-
pete endogenous glycans as acceptor substrates for glycosyl-
transferases. Thus, glycan chain elongation occurs on the
soluble primers rather than on endogenous glycoproteins and
glycolipids, and eventually, the modiﬁed primers are secreted
from the cell (Figure 3A). In recent years, Esko and co-work-
ers have employed a disaccharide primer, R-napthyl
GlcNAc1-3Gal, to inhibit the elaboration of cellular N-acetyl-
lactosamine epitopes with sialic acid (Sia) and fucose (Fuc) res-
idues to form the sialyl Lewis X (sLeX) motif.
35-38 Tumor-
associated sLeX binds to P-selectin, a receptor on activated
endothelial cells, and is thought to mediate the extravasion of
tumor cells from the bloodstream into organs.
39 Treatment of
LS180 cells with the disaccharide primer markedly decreased
cell-surface expression of sLex. The cells displayed diminished
capacity to colonize the lungs of nude mice, suggesting inhi-
bition of this pathway may be a viable approach for control-
ling metastasis.
FIGURE 3. Perturbing glycosylation with synthetic sugars. (A)
Glycosyltransferases add activated glycan donors onto proteins in
the secretory pathway to biosynthesize cell-surface glycoproteins.
(B) Primers of glycosylation divert the action of glycosyltransferases
away from their endogenous substrates. Instead, the primers are
glycosylated at the expense of cellular glycoproteins, and
elaborated primers are secreted. (C) Unnatural monosaccharides
can be metabolically incorporated into glycans, wherein they
prevent further elongation.
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Glycans. Conservative modiﬁcations of monosaccharide struc-
tures are sometimes tolerated by biosynthetic enzymes,
enabling the metabolic incorporation of the sugar analogs into
cellular glycans (Figure 3B). The modiﬁcation can disrupt rec-
ognition by downstream elaborating enzymes, or by recep-
tors that eventually govern the glycan’s function. In a
pioneering study, Reutter and co-workers demonstrated that
unnatural variants of N-acetylmannosamine (ManNAc), in
which the N-acyl substituent is elaborated, are recognized by
the sialic acid biosynthetic machinery. Thus, treatment of cells
with N-propanoylmannosamine (ManNProp) leads to replace-
ment of a fraction of their cell surface sialic acid residues with
the N-propanoyl derivative.
40 This structural perturbation inter-
fered with sialic acid-dependent viral infection.
8
A similar technique was employed to induce premature ter-
mination of glycan chains in neurons. Poly(sialic acid) (PSA), a
homopolymer comprising 2,8-linked sialic acid residues, is a
modiﬁcation of the neural cell adhesion molecule (NCAM) that
has been linked to neuronal plasticity.
41 Neurons grown in the
presence of N-butanoyl mannosamine (ManNBut) were found
to have shortened PSA chains, presumably due to inefﬁcient
extension of PSA polymers incorporating this substrate by
polysialyltransferases.
42 In the future, biosynthetic modula-
tion of PSA length using ManNBut might be applied to stud-
ies of PSA in neuronal development.
In addition to unnatural sialosides, derivatives of N-acetyl-
glucosamine (GlcNAc) and galactose (Gal) have been incorpo-
rated into glycans using cellular machinery. Mice and human
cell lines are able to incorporate 4-ﬂuoro-GlcNAc into mucin-
type O-linked glycans.
43,44 Incorporation of this modiﬁcation
terminates further elongation of glycan chains by removal of
the acceptor nucleophile, thereby diminishing the production
of epitopes that bind to E-selectin, a receptor on activated
endothelial cells involved in inﬂammation. As a consequence,
T-cells do not bind to the endothelial cells and homing to the
inﬂamed tissue is blocked.
In an application to neurobiology, chain-terminating sug-
ars were employed to study the processes of neurite out-
growth and synapse formation. FucR1-2Gal has long been
implicated in cognitive processes.
45 Hsieh-Wilson and
co-workers studied the details of this process through the use
of 2-deoxy-Gal (2-d-Gal), which is incorporated into cellular
glycans thereby blocking formation of the FucR1-2Gal
epitope.
46 Synapsin, a protein involved in neurite outgrowth
and neurotransmitter release, was rapidly degraded by
calpain-mediated proteolysis in the absence of its normal
FucR1-2Gal modiﬁcation. This observation suggests a criti-
cal role for FucR1-2Gal in neuronal plasticity.
“Switchable” Glycosyltransferases. Inhibitors, primers,
and unnatural substrates share the ability to downregulate gly-
cosyation in a temporally controlled manner. However, the
high degree of homology between related glycosyltrans-
ferases makes discrimination between these enzymes with
speciﬁc small molecules a challenge. A complementary
approach that we developed merges genetic and molecular
approches to allow temporal regulation of speciﬁc glycosyl-
transferases using a small molecule switch. The approach
exploits the conserved modular architecture of most Golgi-
resident glycosyltransferases, which comprise functionally dis-
tinct catalytic (CAT) and localization (LOC) domains that must
be physically associated for activity on their cellular substrates.
We fused separated CAT and LOC domains to the FK506
binding protein (FKBP) and the FKB-rapamycin binding domain
(FRB) of the mammalian target of rapamycin (mTOR), respec-
tively.
47 In the absence of rapamycin, FKBP and FRB show
negligible afﬁnity for one another.
48 As a result, the LOC
domain localizes normally to the Golgi membrane, while the
catalytic domain is secreted from the cell, effectively limiting
FIGURE 4. Engineering glycosyltransferases for small molecule
control. (A) In the absence of rapamycin, a “chemical inducer of
dimerization”, catalytic and localization domains remain separate
and the glycosyltransferase cannot engage its substrates. (B) In the
presence of rapamycin, the glycosyltransferase domains associate
and the enzyme regains activity.
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cin initiates heterodimerization of FKBP and FRB, reconstitut-
ing the native localization of the CAT domain and restoring its
enzymatic activity (Figure 4B). The approach was applied to
glycosyltransferases
47,49 and to sulfotransferases
50 that act on
glycans.
Proﬁling Glycosylation
Decoding the information stored in the glycome is a major
impetus of the ﬁeld of glycobiology. Chemical approaches can
vastly accelerate this process by enabling molecular-level anal-
yses of glycans at the systems level. Furthermore, proﬁles of
glycans associated with disease can provide new biomarkers
for diagnosis and therapeutic monitoring.
51,52 Three comple-
mentary approaches for proﬁling glycans are now assuming
prominent positions: lectin/antibody arrays, mass spectrome-
try, and metabolic labeling.
Lectin Microarrays. Lectins are nonantibody carbohydrate
binding proteins that exhibit speciﬁcity for one or more gly-
can-associated epitopes. Historically, lectins have been used in
low-throughput agglutination assays to categorize cell surfac-
es.
53 Advances in microarray technology coupled with the
genome-driven discovery of new lectins have enabled more
rapid and detailed analyses of glycosylation. Recently, Kuno
and co-workers used evanescent ﬂuorescence to quantify the
binding of diverse Cy5-labeled glycoproteins to an array of 39
different lectins.
54 Mahal and co-workers used a similar
approach to characterize bacterial cell surface glycomes.
23 In
an extension of this theme, Haab and co-workers used
microarrayed antibodies to capture speciﬁc glycoproteins from
the serum of healthy donors and cancer patients to individ-
ual array features. Through use of a type of sandwich assay,
lectin binding to the captured species identiﬁed speciﬁc gly-
can changes unique to the cancer patients.
55 While these tech-
niques can detect both the identity and concentration of
certain glycan epitopes, not every glycan structure has a cor-
responding lectin and many lectins show promiscuous bind-
ing. Nonetheless, lectin arrays can provide insight into
glycosylation patterns associated with disease.
Mass Spectrometry. Comprehensive structural analysis of
cell-derived glycans can be achieved using mass spectrome-
try. For decades, mass spectrometry has been the tool of
choice for sequencing the oligosaccharide components of puri-
ﬁed glycoproteins.
56,57 With the advent of ultrasensitive and
ultrahigh-resolution mass spectrometry techniques, entire gly-
comes can now be analyzed from complex cell lysates or
bodily ﬂuids. Already, distinct glycan proﬁles have been iden-
tiﬁed in sera from patients with ovarian,
51 breast,
52 and pros-
tate
58 cancers using mass spectrometry proﬁling techniques.
These discoveries represent the ﬁrst step in identifying new
clinical biomarkers.
Both lectin arrays and mass spectrometric techniques pro-
vide a snapshot of glycosylation at steady state. The dynam-
ics of glycosylation, still difﬁcult to analyze using these
techniques, may provide additional information relevant to
disease monitoring or to fundamental studies of glycobiol-
ogy. For instance, cancer cells are known to metabolize sim-
ple sugars more rapidly than healthy cells, a trait that has
been exploited in diagnostic imaging.
59 Techniques that
assess glycosylation dynamics, including monosaccharide
uptake and processing, glycan biosynthesis, and membrane
turnover, could provide a new dimension to glycome proﬁling.
We have made use of the bioorthogonal chemical reporter
strategy to speciﬁcally tag newly synthesized glycoconjugates,
which can then be puriﬁed and inventoried. In this procedure,
an unnatural monosaccharide containing a small, bioorthogo-
nal functional group is incorporated into glycans using the
cell’s metabolic machinery.
60 Much like a pulse-chase exper-
iment, the incubation time and concentration of the synthetic
sugar can be varied so that it labels only the most recently
synthesized glycans and not the entire glycome. Subsequently,
a reagent speciﬁc for the bioorthogonal functionality is used
to modify the newly synthesized glycans with a probe for cap-
ture and enrichment (Figure 5A).
The azide has proven to be the most versatile bioorthogo-
nal functional group for metabolic labeling of glycans, because
it is small, abiotic, and stable in cellular systems. Sia,
61 Gal-
NAc,
62 GlcNAc,
63 and Fuc
64,65 can all be substituted with azido
analogs in cultured cells, and Sia and GalNAc can be labeled
with azides in mice (Figure 5B). In contrast to chain termina-
tors, the azide-bearing sugars are not intended to disrupt fur-
ther glycan elaboration and are generally well-tolerated by
cultured cells and mice.
62,66,77 Once installed in a glycan, the
azide can be selectively reacted with phosphines via the
Staudinger ligation, with terminal alkynes via Cu-mediated
“click chemistry”, or with cyclooctynes by a strain-promoted [3
+ 2] cycloaddition
65,67-70 (Figure 5C). These reactions allow
chemical labeling of the azido glycan with any probe of choice
(e.g., biotin, FLAG peptide, or ﬂuorescent dyes). Fucose and
sialic acids modiﬁed by terminal alkynes can also be incorpo-
rated onto cell surfaces and imaged via click chemistry (Fig-
ure 5B);
65,71 however, the inherent toxicity of the copper
reagents precludes imaging of live organisms.
The bioorthogonal chemical reporter strategy has been art-
fully employed in the proteomic analysis of protein O-GlcNA-
cylation, a form of glycosylation that is unique to cytosolic and
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tein function.
6 Despite its potential importance, the complete
repertoire of O-GlcNAcylated proteins is not known. We dem-
onstrated that GlcNAcylated proteins can be metabolically
labeled with the azido analog N-azidoacetylglucosamine
(GlcNAz), and then biotinylated by Staudinger ligation with a
phosphine probe.
63 Zhao and co-workers exploited this dis-
covery to capture O-GlcNAcylated proteins for a comprehen-
sive proteomic analysis of cell lysates.
72
In another application, the bioorthogonal chemical reporter
method was applied to analyze mucin-type O-linked glyco-
proteins from cell lysates
62 and murine tissues.
73 N-Azi-
doacetylgalactosamine (GalNAz) was found to label the
O-linked glycans in both contexts, substituting for the con-
served glycan core residue GalNAc. Interestingly, the GalNAz
labeling efﬁciency of B cells from treated mice was consider-
ably higher than that of T cells, a result that was not predicted
based on their steady-state glycomes. This observation under-
scores the differences in information provided by metabolic
labeling versus lectin or mass spectrometry methods of gly-
can proﬁling.
Perceiving Glycans
To understand how changes in glycosylation relate to physi-
ological changes requires a means to visualize these biopoly-
mers in a physiologically relevant context. Tagging proteins
with ﬂuorescent-protein fusions has proven to be an invalu-
able technique for tracking their localization and function in
living cells. Analogous tools should be sought for probing the
abundance, distribution, and dynamics of glycans in vivo. The
bioorthogonal chemical reporter strategy holds much prom-
ise in this regard. Glycans can be labeled with SiaNAz and Gal-
NAz in living animals.
66,73 In addition, phosphine probes
injected into these animals undergo the Staudinger ligation
and accumulate on cell surfaces in an azide-dependent man-
ner. The stage has thus been set for the delivery of imaging
probes that can report on the presence of speciﬁc glycan
subtypes.
The development of imaging reagents that target azides is
an important next step. Two recent examples include the
development of phosphine- or alkyne-functionalized dyes that
ﬂuoresce only upon reaction with azides and thereby label cell
surface glycans with low background staining.
65,71,74 The
application of these reagents in living animals, however, may
be limited. The Staudinger ligation is plagued by slow kinet-
ics and the Cu-mediated “click chemistry” requires a toxic
heavy metal catalyst. To overcome these problems, we
recently developed a diﬂuorinated cyclooctyne reagent,
termed DIFO (Figure 5C(iii)) that rapidly reacts with azides and
is nontoxic in mice.
75,76 The rapid kinetics of DIFO-azide
reactions were exploited to monitor the dynamics of cellular
glycosylation during zebraﬁsh embryo development. Zebraﬁsh
embryos labeled with GalNAz were tagged with ﬂuorescently
labeled DIFO reagents to image the ﬁsh’s total O-linked gly-
cosylation.
77 We extended this technique to monitor dynamic
glycosylation by quenching unreacted azide groups on labeled
cells with TCEP, pulsing the embryos with additional GalNAz,
and probing the embryos with a blue-shifted DIFO conjugate
(Figure 6). Areas of rapid O-linked glycan biosynthesis includ-
ing the ﬁns, jaw, and olfactory organs showed increased label-
ing with the blue-shifted conjugate. This quench, label, tag
sequence exploits the high reactivity of DIFO to visualize gly-
FIGURE 5. The bioorthogonal chemical reporter strategy for
proﬁling and visualizing glycans. (A) Metabolic labeling of cell-
surface glycans with an azidosugar. The azide and alkyne
functionalities can be covalently reacted with a probe that bears
the functionality shown in panel C. (B) Azidosugars and alkynyl
sugars that have been employed as metabolic labels. The unnatural
monosaccharides are typically used in peracetylated form to
facilitate cellular uptake. (C) Reagents for covalent labeling of azides
(i, iii) and alkynes (ii): (i) phosphines for the Staudinger ligation; (ii)
terminal alkynes or azides and copper(I) for copper-mediated
azide-alkyne cylcoaddition, “click chemistry”; (iii) diﬂuorinated
cyclooctyne (DIFO) for strain-promoted cycloadditions.
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phosphine probes. In addition, these small molecule-based
reagents are more accessible to the tissues than lectin or anti-
body-based imaging agents. Post-labeling, the zebraﬁsh
appeared to continue normal development, conﬁrming the
low toxicity of these reagents. The extension of this work to
mammalian systems should enable imaging of tumors and
sites of microbial infection.
Future Outlook
Chemical tools for perturbing, proﬁling, and perceiving gly-
cans should reduce the barriers that have previously impeded
progress in this ﬁeld. Their implementation has already pro-
duced a body of knowledge that was formerly limited to the
domain of proteins and nucleic acids. For example, a devel-
oping glycomic database has begun to facilitate bioinformat-
ics studies on glycans.
78 As mentioned above, proﬁles of
glycans from tissues and bodily ﬂuids have produced new
biomarker candidates. Many regents for perturbing glycans,
including inhibitors and primers, are now commercially avail-
able. Similarly, azidosugars and both phosphine- and alkyne-
based labeling reagents can now be obtained from
commercial suppliers. The future is bright for use of these
tools in analyzing the dynamic glycomes of normal and dis-
eased tissues.
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